64 related articles for article (PubMed ID: 11299782)
41. Effects of triple therapy with octreotide, galanin and serotonin on a human colon cancer cell line implanted in mice: comparison between different routes of administration.
El-Salhy M
Histol Histopathol; 2005 Jan; 20(1):19-25. PubMed ID: 15578418
[TBL] [Abstract][Full Text] [Related]
42. A comparison between double and triple therapies of octreotide, galanin and serotonin on a rat colon carcinoma.
Sitohy B; El-Salhy M
Histol Histopathol; 2003 Jan; 18(1):103-10. PubMed ID: 12507289
[TBL] [Abstract][Full Text] [Related]
43. [The use of Sandostatin in the combined treatment of surgical diseases of the pancreas].
Saenko VF; Lifshits IuZ; Kozhara SP; Usenko AIu; Andreeshchev SA; Kryzhevskiĭ VV; Olenin VV; Beliaeva OA
Lik Sprava; 1997; (3):126-7. PubMed ID: 9377332
[TBL] [Abstract][Full Text] [Related]
44. Frequent development of pancreatic carcinomas in the Rana nigromaculata group.
Masahito P; Nishioka M; Ueda H; Kato Y; Yamazaki I; Nomura K; Sugano H; Kitagawa T
Cancer Res; 1995 Sep; 55(17):3781-4. PubMed ID: 7641193
[TBL] [Abstract][Full Text] [Related]
45. Proceedings of the 1st Annual Octreotide LAR Investigators' Workshop in Oncology. Role of Octreotide in Cancer and Therapy-Related Complications. April 2002.
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 8):7-24. PubMed ID: 12387268
[No Abstract] [Full Text] [Related]
46. The effect of octreotide on parathyroid carcinoma.
Denney AM; Watts NB
J Clin Endocrinol Metab; 2004 Feb; 89(2):1016. PubMed ID: 14764832
[No Abstract] [Full Text] [Related]
47. Establishment and characterization of a new transplantable pancreatic cancer xenograft (PZX-5) in immunosuppressed mice.
Zalatnai A; Bocsi J; Timár F; Babó I
Int J Pancreatol; 1998 Feb; 23(1):51-62. PubMed ID: 9520091
[TBL] [Abstract][Full Text] [Related]
48. Human pancreatic leiomyosarcoma (PZX-7) growing as a serially transplantable xenograft in immunosuppressed mice.
Zalatnai A; Bocsi J; Csákány T; Fekete T; Lásztity J
Int J Pancreatol; 1999 Aug; 26(1):33-41. PubMed ID: 10566156
[TBL] [Abstract][Full Text] [Related]
49. Pancreatic cancer - a continuing challenge in oncology.
Zalatnai A
Pathol Oncol Res; 2003; 9(4):252-63. PubMed ID: 14688834
[TBL] [Abstract][Full Text] [Related]
50. Pancreatic cancer: does octreotide offer any promise?
Rosenberg L
Chemotherapy; 2001; 47 Suppl 2():134-49. PubMed ID: 11275707
[TBL] [Abstract][Full Text] [Related]
51. Apoptosis-induction and phosphorylation state in human pancreatic carcinoma xenografts following octreotide treatment.
Zalatnai A; Pogány V
Anticancer Res; 2001; 21(1A):477-80. PubMed ID: 11299782
[TBL] [Abstract][Full Text] [Related]
52. Short-term octreotide treatment induces apoptosis in human pancreatic cancer xenografts.
Zalatnai A; Bocsi J
In Vivo; 2006; 20(4):549-52. PubMed ID: 16900788
[TBL] [Abstract][Full Text] [Related]
53. Flow cytometric evidence of apoptosis in human pancreatic cancer xenografts treated with Sandostatin (octreotide).
Zalatnai A; Szegedi Z; Bocsi J
Anticancer Res; 2000; 20(3A):1663-6. PubMed ID: 10928088
[TBL] [Abstract][Full Text] [Related]
54. Medroxyprogesterone acetate inhibits human pancreatic carcinoma cell growth by inducing apoptosis in association with Bcl-2 phosphorylation.
Abe M; Yamashita J; Ogawa M
Cancer; 2000 May; 88(9):2000-9. PubMed ID: 10813710
[TBL] [Abstract][Full Text] [Related]
55. Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice.
Weckbecker G; Raulf F; Bodmer D; Bruns C
Yale J Biol Med; 1997; 70(5-6):549-54. PubMed ID: 9825482
[TBL] [Abstract][Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
